Please wait while the formulary information is being retrieved.
REGEN-COV (EUA) (casirivimab (REGN10933)/imdevimab (REGN10987))
120 mg/mL-120 mg/mL intravenous solution
- Dosage information is not available
60 mg-60 mg/mL intravenous solution
- Infuse 10 milliliters (1,200 mg total dose) by intravenous route onceper protocol
Default screening record
- Inject 10 milliliters (1,200 mg total dose) as 4 consecutive 2.5 ml injections by subcutaneous route once per protocol
- Infuse 10 milliliters (1,200 mg total dose) by intravenous route onceper protocol
- Infuse 5 milliliters (600 mg total dose) by intravenous route every 4Weeks per protocol
- Inject 5 milliliters (600 mg total dose) as 2 consecutive 2.5 ml injections by subcutaneous route every 4 weeks per protocol
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
REGEN-COV (EUA) (casirivimab (REGN10933)/imdevimab (REGN10987))
- None
- None
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Bronchospastic pulmonary disease
- Hypersensitivity drug reaction
- Hypotension
Less Severe
- Chills
- Dizziness
- Fever
- Headache disorder
- Myalgia
- Nausea
- Pharyngitis
- Pruritus of skin
- Skin rash
- Urticaria
Contraindicated
None
Severe Precaution
Casirivimab and Imdevimab
Not authorized for patients < 12 years of age; no safety and effectiveness established.
- 1 Day – 12 Years
- Not authorized for patients < 12 years of age; no safety and effectiveness established.
Management or Monitoring Precaution
Casirivimab and Imdevimab
Not authorized for low-risk pediatric patients or patients weighing < 40 kg; no safety and effectiveness established.
- 12 Years – 18 Years
- Not authorized for low-risk pediatric patients or patients weighing < 40 kg; no safety and effectiveness established.
Casirivimab And Imdevimab
- Severity Level:
2
- Additional Notes: Insufficient human data available, assess risk/benefit
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Casirivimab And Imdevimab
Insufficient human data avail; consider risk/benefit
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data avail; consider risk/benefit |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Formulary Reference Tool